Immunome, Inc. (IMNM)

15.75 +0.78 (+5.21%) At close: 04:00PM EDT

Immunome, Inc.

18702 N. Creek Parkway
Suite 100
Bothell, WA 98011
United States
610-321-3700
https://immunome.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 55

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Clay B. Siegall Ph.D.	President, CEO & Chairman	1.43M	N/A	1961

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Corporate Governance

Immunome, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.